GlassScriptPhysician profile
William G Stephens
NPI 1417247446
$2,662.46
in general payments reported to CMS, 2019-2025
30 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $192 · 2021: $270 · 2022: $405 · 2023: $470 · 2024: $312 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $516.66 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Osteocool Rf Ablation System |
| Boston Scientific Corporation | $497.49 | 2019-2023 | Infinion 16, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $314.76 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $131.93 | 2019-2025 | Belbuca |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Painteq LLC | $115.73 | 2023 | Painteq |
| Vertiflex, INC. | $105.65 | 2019 | |
| Nevro Corp. | $88.70 | 2019-2022 | |
| Mml US, INC. | $85.50 | 2025 | Reactiv8 |
| Pfizer INC. | $64.59 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $59.46 | 2025 | |
| Averitas Pharma INC. | $54.13 | 2023-2024 | Qutenza |
| Amgen INC. | $53.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.35 | 2019-2024 | Relistor |
| Daiichi Sankyo INC. | $41.59 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $40.09 | 2019 | |
| Merck Sharp & Dohme LLC | $39.51 | 2019-2020 | |
| Medtronic USA, INC. | $36.38 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $30.71 | 2022 | |
| Biotronik Nro, INC. | $28.12 | 2025 | Prospera |
| Abbvie INC. | $24.47 | 2022 | |
| Relievant Medsystems, INC. | $23.21 | 2023 | Intracept |
| Fidia Pharma USA INC. | $19.88 | 2022 | |
| Foundation Fusion Solutions, LLC | $19.51 | 2023 | |
| Protega Pharmaceutials INC | $18.96 | 2025 | Roxybond |
| Ucb, INC. | $18.87 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.25 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $17.11 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.81 | 2019 | |
| Lilly USA, LLC | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.